ABL enters into contract with AEEH for development of HepatiC software
Under the agreement, ABL will provide national access to the HepatiC program to the Spanish Community of Hepatologists and be responsible for development, maintenance and improvement of the software. HepatiC is designed to help manage patients with hepatitis C infections, particularly patients undergoing Direct Acting Antiviral therapy.
"The HepatiC initiative in Spain will facilitate the creation of a national HCV patient Registry and Database," Head of the Internal Medicine and Hepatology Department at the Hospital Vall d'Hebron in Barcelona Rafael Esteban said. "This tool is key to the support of our epidemiological studies, the monitoring of patient outcomes and the reporting to regional national and international institutions."
ABL will be in charge of expanding the HepatiC market to include countries outside of Spain.
"We are honored to be working with the AEEH and the Spanish experts on liver diseases and to share our respective knowledge with them," ABL Chief Executive Officer Dr. Chalom Sayada said. "HepatiC shall reinforce ABL business in viral hepatitis infectious diseases and oncology in the near future in several continents."